Annals of Surgical Oncology

, Volume 19, Issue 6, pp 1928–1935 | Cite as

Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment

  • George A. Poultsides
  • Lyen C. Huang
  • John L. Cameron
  • Richard Tuli
  • Leslie Lan
  • Ralph H. Hruban
  • Timothy M. Pawlik
  • Joseph M. Herman
  • Barish H. Edil
  • Nita Ahuja
  • Michael A. Choti
  • Christopher L. Wolfgang
  • Richard D. Schulick
Gastrointestinal Oncology



Duodenal adenocarcinoma is a rare cancer usually studied as a group with periampullary or small bowel adenocarcinoma; therefore, its natural history is poorly understood.


Patients with duodenal adenocarcinoma were identified from a single-institution pancreaticoduodenectomy database. Patients with adenocarcinoma arising from the ampulla of Vater were excluded. Univariate and multivariate analyses were performed to identify clinicopathologic variables associated with survival and recurrence after resection.


From 1984 to 2006, a total of 122 patients with duodenal adenocarcinoma underwent pancreaticoduodenectomy. Overall survival after resection was 48% at 5 years and 41% at 10 years. Five-year survival decreased as the number of lymph nodes involved by metastasis increased from 0 to 1–3 to ≥4 (68%, 58%, 17%, respectively, P < 0.01) and as the lymph node ratio increased from 0 to >0–0.2 to >0.2–0.4 to >0.4 (68%, 57%, 14%, 14%, respectively, P < 0.01). Lymph node metastasis was the only independent predictor of decreased survival in multivariate analysis. Recurrence after resection was predominantly distant (81%). Adjuvant chemoradiation did not decrease local recurrence or prolong overall survival; however, patients who received chemoradiation more commonly had nodal metastasis (P = 0.03).


The prognostic significance of both the absolute number and ratio of involved lymph nodes emphasizes the need for adequate lymphadenectomy to accurately stage duodenal adenocarcinoma. The mostly distant pattern of recurrence underscores the need for the development of effective systemic therapies.


Perineural Invasion Adjuvant Chemoradiotherapy Adjuvant Chemoradiation Synchronous Liver Metastasis Small Bowel Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998;227:821–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRefGoogle Scholar
  4. 4.
    Agrawal S, McCarron EC, Gibbs JF, et al. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol. 2007;14:2263–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg. 2007;142:229–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Ouriel K, Adams JT. Adenocarcinoma of the small intestine. Am J Surg. 1984;147:66–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Barnes G, Romero L, Hess KR, et al. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994;1:73–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Kaklamanos IG, Bathe OF, Franceschi D, et al. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179:37–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Ryder NM, Ko CY, Hines OJ, et al. Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg. 2000;135:1070–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Sarela AI, Brennan MF, Karpeh MS, et al. Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer. Ann Surg Oncol. 2004;11:380–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Alwmark A, Andersson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg. 1980;191:13–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Lowell JA, Rossi RL, Munson JL, et al. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127:557–60.CrossRefGoogle Scholar
  13. 13.
    Delcore R, Thomas JH, Forster J, et al. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166:626–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Rotman N, Pezet D, Fagniez PL, et al. Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research. Br J Surg. 1994;81:83–5.Google Scholar
  15. 15.
    Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135:635–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Hurtuk MG, Devata S, Brown KM, et al. Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection? Am J Surg. 2007;193:319–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Han SL, Cheng J, Zhou HZ, et al. The surgical treatment and outcome for primary duodenal adenocarcinoma. J Gastrointest Cancer. 2009;40:33–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Struck A, Howard T, Chiorean EG, et al. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol. 2009;100:144–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee HG, You DD, Paik KY, et al. Prognostic factors for primary duodenal adenocarcinoma. World J Surg. 2008;32:2246–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Sexe RB, Wade TP, Virgo KS, et al. Incidence and treatment of periampullary duodenal cancer in the U.S. veteran patient population. Cancer. 1996;77:251–4.Google Scholar
  21. 21.
    Sohn TA, Lillemoe KD, Cameron JL, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg. 1998;2:79–87.PubMedCrossRefGoogle Scholar
  22. 22.
    Kelsey CR, Nelson JW, Willett CG, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:1436–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRefGoogle Scholar
  24. 24.
    R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing Development Core Team, 2007.Google Scholar
  25. 25.
    Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) staging manual. 7th ed. New York: Springer-Verlag, 2010.Google Scholar
  26. 26.
    Nicholl MB, Ahuja V, Conway WC, et al. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol. 2010;17:2728–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Gibbs JF. Duodenal adenocarcinoma: is total lymph node sampling predictive of outcome? Ann Surg Oncol. 2004;11:354–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection—long term results. Br J Surg. 2005;92:547–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg. 2004;240:738–45.PubMedCrossRefGoogle Scholar
  30. 30.
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Swartz MJ, Hughes MA, Frassica DA, et al. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg. 2007;142:285–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Overman MJ, Kopetz S, Wen S, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008;113:2038–45.PubMedCrossRefGoogle Scholar
  33. 33.
    Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–603.PubMedCrossRefGoogle Scholar
  34. 34.
    Gibson MK, Holcroft CA, Kvols LK, et al. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10:132–7.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • George A. Poultsides
    • 1
    • 2
  • Lyen C. Huang
    • 2
  • John L. Cameron
    • 1
  • Richard Tuli
    • 3
  • Leslie Lan
    • 4
    • 5
    • 7
  • Ralph H. Hruban
    • 6
  • Timothy M. Pawlik
    • 1
  • Joseph M. Herman
    • 3
  • Barish H. Edil
    • 1
  • Nita Ahuja
    • 1
  • Michael A. Choti
    • 1
  • Christopher L. Wolfgang
    • 1
  • Richard D. Schulick
    • 1
  1. 1.Department of SurgeryJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of SurgeryStanford University School of MedicineStanfordUSA
  3. 3.Department of Radiation Oncology and Molecular Radiation SciencesJohns Hopkins Medical InstitutionsBaltimoreUSA
  4. 4.Departments of Epidemiology and BiostatisticsBloomberg School of Public HealthBaltimoreUSA
  5. 5.Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimoreUSA
  6. 6.Department of PathologyJohns Hopkins Medical InstitutionsBaltimoreUSA
  7. 7.AlphaDetail Inc.San MateoUSA

Personalised recommendations